UY36336A - Polvo seco para una formulación para inhalar que tiene una estabilidad mejorada de los principios activos combinados - Google Patents

Polvo seco para una formulación para inhalar que tiene una estabilidad mejorada de los principios activos combinados

Info

Publication number
UY36336A
UY36336A UY0001036336A UY36336A UY36336A UY 36336 A UY36336 A UY 36336A UY 0001036336 A UY0001036336 A UY 0001036336A UY 36336 A UY36336 A UY 36336A UY 36336 A UY36336 A UY 36336A
Authority
UY
Uruguay
Prior art keywords
dry powder
formulation
inhalate
weight
combined active
Prior art date
Application number
UY0001036336A
Other languages
English (en)
Inventor
Cho Hyuk Jun
Yoon Young Min
Kim Kyeong Soo
Park Jae Hyun
Woo Jong Soo
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of UY36336A publication Critical patent/UY36336A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Un polvo seco para una formulación para inhalar y una formulación para inhalar que incluye el polvo seco. El polvo seco incluye: al menos dos principios activos combinados seleccionados a partir del grupo constituido por salmeterol o una de sus sales farmacéuticamente aceptables, tiotropio o una de sus sales farmacéuticamente aceptables y fluticasona o una de sus sales farmacéuticamente aceptables; y un diluyente, donde el diluyente incluye entre aproximadamente un 0.1% en peso y aproximadamente un 50% en peso de polvo micronizado que tiene un diámetro de partícula promedio (X50) igual o inferior a aproximadamente 30 µm en función del peso total del diluyente, de modo que la estabilidad de al menos uno de los principios activos es superior a la de un polvo seco que tiene un contenido en polvo micronizado superior a un 50% en peso.
UY0001036336A 2014-09-30 2015-09-29 Polvo seco para una formulación para inhalar que tiene una estabilidad mejorada de los principios activos combinados UY36336A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20140132006 2014-09-30

Publications (1)

Publication Number Publication Date
UY36336A true UY36336A (es) 2016-04-01

Family

ID=55630875

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001036336A UY36336A (es) 2014-09-30 2015-09-29 Polvo seco para una formulación para inhalar que tiene una estabilidad mejorada de los principios activos combinados

Country Status (5)

Country Link
KR (1) KR20160038767A (es)
AR (1) AR102108A1 (es)
TW (1) TW201618759A (es)
UY (1) UY36336A (es)
WO (1) WO2016052897A1 (es)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0012260D0 (en) * 2000-05-19 2000-07-12 Astrazeneca Ab Novel composition
GB0208609D0 (en) * 2002-04-13 2002-05-22 Glaxo Group Ltd Compositions
WO2005087192A2 (en) * 2004-03-12 2005-09-22 Cipla Limited Salmeterol inhalation formulations
TR201000681A2 (tr) * 2010-01-29 2011-08-22 B�Lg�� Mahmut İnhalasyon yoluyla alınan kuru toz formülasyonları.
KR20130140358A (ko) * 2012-06-14 2013-12-24 한미약품 주식회사 살메테롤 지나포산염, 플루티카손 프로피오네이트 및 티오트로피움 브로마이드를 포함하는 흡입 제형용 건조 분말 및 이의 제조방법

Also Published As

Publication number Publication date
KR20160038767A (ko) 2016-04-07
AR102108A1 (es) 2017-02-01
WO2016052897A1 (en) 2016-04-07
TW201618759A (zh) 2016-06-01

Similar Documents

Publication Publication Date Title
SV2016005236A (es) Formulación compuesta para administración oral que comprende ezetimibe y rosuvastatina
CL2017001488A1 (es) Benzamidas sustituidas con 1,3–tiazol–2–ilo
CL2016002148A1 (es) Derivados de fenilen-1,5-diamina 2,4-disustituidos y aplicaciones de los mismos, y composiciones farmacéuticas y composiciones farmacéuticamente aceptables preparadas a partir de los mismos.
UY36275A (es) Compuestos aminopirimidinilo
BR112017007460A2 (pt) inibidores de di-hidropirrolopiridina de ror-gama
CL2015002860A1 (es) Antagonistas de la alfa-v-beta-6 integrina
AR088382A1 (es) Formulaciones de etanercept estabilizadas con xilitol
CL2018001510A1 (es) Composición farmacéutica que comprende un potente inhibidor de urat1
SV2017005596A (es) Unidad de dosificacion orodispersable que contiene un componente estetrol
GT201700023A (es) Derivados de heterociclico opcionalmente condensados de piridimina útiles para el tratamiento de enfermedades inflamatorias, metabolicas, oncológicas y autoinmunitarias
CL2018000249A1 (es) Inhibidor de la isocitrato deshidrogenasa mutada idh1 r132h
BR112016025910A8 (pt) uso de uma quantidade eficaz de glyx-13, uso de glyx-13 e um antagonista de nmdar e composição farmaceuticamente aceitável compreendendo os mesmos
WO2015168635A3 (en) Compositions and methods for modulating complement factor b expression
UY35298A (es) Formulación en dispersión sólida de un compuesto antiviral
UY36703A (es) Composiciones y métodos para la administración de un polinucleótido en una planta
BR112015017251A2 (pt) composições farmacêuticas compreendendo doadores de nitroxil
MA40583A (fr) Nouveaux activateurs de la guanylate cyclase soluble et leur utilisation
CL2016001094A1 (es) Silicato de zirconio microporoso para el tratamiento de hipercalemia.
BR112015027017A2 (pt) composições farmacêuticas inaláveis e dispositivos inaladores que contêm as mesmas
CL2016000300A1 (es) Métodos terapéuticos
AR090073A1 (es) N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinolinacarboxamida, su preparacion y usos
AR090975A1 (es) N-etil-4-hidroxil-1-metil-5-(metil(2,3,4,5,6-pentahidroxihexil)amino)-2-oxo-n-fenil-1,2-dihidroquinolina-3-carboxamida
CL2015002702A1 (es) Composiciones farmacéuticas micronizadas.
MY191712A (en) Composition comprising at least one dry powder obtained by spray drying to increase the stability of the formulation
BR112016009214A8 (pt) uso de um composto para preparação de um medicamento para o tratamento de distrofia muscular e composição farmacêutica

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20220705